Nephrogenic Diabetes Insipidus
📧 Sign up to get email alerts when something new happens for Nephrogenic Diabetes Insipidus.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-01-27Clinical Trial Update: Probenecid (PB) to Treat Hereditary Nephrogenic Diabetes Insipidus (NDI), ADPKD Treated With Tolvaptan, and Severely Polyuric Patients With Previous Lithium Administration [Phase 2]
Phase 2 clinical trial evaluating probenecid for hereditary nephrogenic diabetes insipidus, with autosomal dominant polycystic kidney diseas…
-
CLINICAL_TRIALS research · 2025-05-09Clinical Trial Update: AMIloride for the Treatment of Nephrogenic Diabetes Insipidus for Patients With Bipolar Disorder Treated With Lithium [Phase 4]
Phase 4 clinical trial evaluating amiloride for nephrogenic diabetes insipidus in patients with bipolar disorder treated with lithium; trial…
-
CLINICAL_TRIALS research · 2025-02-13Clinical Trial Update: Arginin-stimulated Copeptin in Polyuria-polydipsia Syndrome in Children [NA]
A pediatric trial evaluating arginine-stimulated copeptin for diagnosing polyuria-polydipsia syndrome, including primary polydipsia and cent…
-
FDA approval · 2024-04-30FDA Approved: HYDROCHLOROTHIAZIDE — Supplemental Application (Accord Healthcare Inc.)
The FDA approved a supplemental application for hydrochlorothiazide filed by Accord Healthcare Inc. under ANDA 202556. The document does not…
-
FDA approval · 2023-03-16FDA Approved: HYDROCHLOROTHIAZIDE — Supplemental Application (Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc.)
The FDA approved a supplemental application for Hydrochlorothiazide submitted by Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals In…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-09-16Clinical Trial Update: Atorvastatin for the Treatment of Lithium-Induced Nephrogenic Diabetes Insipidus [Phase 2]
Phase 2 clinical trial investigating atorvastatin for lithium-induced nephrogenic diabetes insipidus has completed.
-
FDA approval · 2020-08-20FDA Approved: HYDROCHLOROTHIAZIDE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for Hydrochlorothiazide from Aurobindo Pharma Limited. The decision updates the approved generic pro…
-
CLINICAL_TRIALS trial_result · 2018-07-17Clinical Trial Update: Metformin and Congenital Nephrogenic Diabetes Insipidus [Phase 1]
Phase 1 trial of metformin for nephrogenic diabetes insipidus led by Emory University has been terminated.
-
CLINICAL_TRIALS trial_result · 2018-02-12Clinical Trial Update: Pharmacologic Treatment of Congenital Nephrogenic Diabetes Insipidus [NA]
Clinical trial on pharmacologic treatment for nephrogenic diabetes insipidus has completed with results posted in 2018.
-
FDA approval · 2016-03-07FDA Approved: HYDROCHLOROTHIAZIDE — Supplemental Application (Exelan Pharmaceuticals Inc.)
The FDA approved a supplemental application for hydrochlorothiazide filed by Exelan Pharmaceuticals Inc. (ANDA).
-
FDA approval · 2014-07-23FDA Approved: HYDROCHLOROTHIAZIDE — Original Application (ScieGen Pharmaceuticals, Inc.)
FDA approved the original application for Hydrochlorothiazide (ScieGen Pharmaceuticals, Inc.), a generic diuretic. It is indicated for hyper…
-
FDA approval · 2008-08-15FDA Approved: HYDROCHLOROTHIAZIDE — Original Application (Exelan Pharmaceuticals Inc.)
The FDA approved Exelan Pharmaceuticals Inc.'s original application for hydrochlorothiazide, a generic diuretic indicated for hypertension a…